<DOC>
	<DOCNO>NCT00633204</DOCNO>
	<brief_summary>The purpose study evaluate clinical efficacy prevention recurrence bladder cancer TUR-Bt</brief_summary>
	<brief_title>Peptide Vaccine Focusing Prevention Recurrence Bladder Cancer</brief_title>
	<detailed_description>DEP domain contain 1 ( DEPDC1 ) M phase phosphoprotein 1 ( MPHOSPH1 ) identify use genome-wide expression profile analysis use cDNA microarray previous study . The investigator determine HLA-A*2402 restrict epitope peptide derive DEPDC1 , DEPDC1-9-294 , MPHOSPH1 , MPHOSPH1-9-278 . These epitope show strong IFN-g production stimulate appropriate target express appropriate protein HLA-A*2402 . Furthermore , vaccinate peptide , specific CTLs determine vaccination . Therefore focused prevention recurrence bladder cancer surgery use peptide .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>Inclusion Criteria DISEASE CHARACTERISTICS 1 . Bladder cancer without solitary low grade tumor 2 . Protein expression MPHOSPH1 DEPDC1 tumor PATIENTS CHARACTERISTICS 1 . Patients must treat completely Transurethral resection bladder tumor ( TURBt ) , must residual tumor reTURBt . 2 . Patients without first time , solitary , low grade1 bladder cancer , tumor diagnose histologically transitional cell carcinoma bladder . 3 . Patients must treat TURBT , able treat Intravesical Bacillus calmetteguerin ( BCG ) adjuvant therapy 4 . ECOG performance status 0 1 5 . Age ≥ 20 year , ≤80 year 6 . WBC≥ 2,000/mm³ , ≤15000/mm³ Platelet count ≥ 75000/mm³ AST , ALT ≤150 IU/l Total bilirubin ≤ 3.0 mg/dl Creatinine ≤ 3.0 mg/dl 7 . Samples bladder cancer must express MPHOSPH1 DEPDC1 8 . Able willing give valid write informed consent 1 . Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) 2 . Breastfeeding 3 . Patients willing childbearing ( Refusal inability use effective mean contraception ) 4 . Serious infection require antibiotic 5 . Concomitant treatment steroid immunosuppressing agent 6 . Other malignancy difficult control . 7 . Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Epitope peptide , CTL , TUR-Bt , Bladder cancer , Vaccination</keyword>
	<keyword>Bladder cancer surgery</keyword>
</DOC>